The therapeutic outcomes and adverse drug reactions study of Clozapine on Schizophrenia inpatients in the Grhasia psychiatric hospital Yogyakarta, Indonesia

被引:0
作者
Harjaningsih, Woro [1 ]
Ayunirrahmah, Laila [2 ]
Putri, Nur Jannah Virsya [2 ]
机构
[1] Univ Gadjah Mada, Fac Pharm, Div Pharmacol & Clin Pharm, Yogyakarta, Indonesia
[2] Univ Gadjah Mada, Fac Pharm, Yogyakarta, Indonesia
来源
PHARMACY EDUCATION | 2021年 / 21卷 / 02期
关键词
Adverse drug reaction; Clozapine; Schizophrenia; Therapeutic outcome; INDUCED WEIGHT-GAIN; HTR2C GENE;
D O I
10.46542/pe.2021.212.287295
中图分类号
G40 [教育学];
学科分类号
040101 ; 120403 ;
摘要
Introduction: Clozapine is an antipsychotic agent used in schizophrenia recurrence or when other antipsychotics are not effective. Aims: This study aims to determine the therapeutic outcome and adverse drug reactions of clozapine in schizophrenia disorder among hospitalised patients. Methods: A retrospective cross-sectional study was conducted between January 2018 and December 2019 using inpatients' medical records from the Grhasia Psychiatric Hospital, Yogyakarta. The therapeutic outcome was measured with the PANSS-EC scale, while adverse drug reactions of clozapine were analysed theoretically as per the literature. Results: The average decrease in the PANSS-EC score was 8.27, and the average duration to achieve this decrease was 2.5 days. The combination of typical-atypical antipsychotics could reduce the highest PANSS-EC score of 11-15 (41%). The adverse drug reactions of clozapine were tremor, weight gain, obesity, leucopenia, hyperglycemia, and hypercholesterolemia, among other effects. Conclusion: Clozapine is effective in improving positive and negative symptoms, but its use needs close monitoring.
引用
收藏
页码:287 / 295
页数:9
相关论文
共 35 条
[11]   Second-Generation Antipsychotics and Extrapyramidal Adverse Effects [J].
Divac, Nevena ;
Prostran, Milica ;
Jakovcevski, Igor ;
Cerovac, Natasa .
BIOMED RESEARCH INTERNATIONAL, 2014, 2014
[12]   Employment and Schizophrenia: Three Innovative Research Approaches [J].
Drake, Robert E. .
SCHIZOPHRENIA BULLETIN, 2018, 44 (01) :20-21
[13]  
Durand V.M., 2007, INTISARI PSIKOLOGI A, V4th
[14]  
Fahrul F., 2014, ONLINE J NATURAL SCI, V3, P18
[15]  
Gemilang B.M., 2017, E JURNAL MEDIKA, V6, P61
[16]  
Hariyanto I., 2016, JURNAL FARMASI KLIN, V5, P115, DOI [10.15416/ijcp.2016.5.2.115, DOI 10.15416/IJCP.2016.5.2.115]
[17]  
Ikawati Z., 2014, FARMAKOTERAPI SISTEM
[18]  
Indriani A., 2019, MAJALAH FARMASETIKA, V4, P201, DOI [10.24198/mfarmasetika.v4i0.25882, DOI 10.24198/MFARMASETIKA.V4I0.25882]
[19]  
Iqbal Mohammad Masud, 2003, Ann Clin Psychiatry, V15, P33, DOI 10.1023/A:1023228626309
[20]  
Juleha J., 2019, J BASIC CLIN PHYSIOL